Cardior Pharmaceuticals

Cardior Pharmaceuticals is a biotechnology company engaged in the development of non-coding RNA therapies for the treatment and prevention of heart diseases. The company focuses on developing CDR-132X, an oligonucleotide-based molecular master switch (microRNA) inhibitor, to control pathological changes in the heart after stress or injury. Cardior Pharmaceuticals serves the healthcare industry in Germany.